TY - JOUR
T1 - An Enthalpy-Balance Model for Timewise Evolution of Temperature during Wet Stirred Media Milling of Drug Suspensions
AU - Guner, Gulenay
AU - Elashri, Sherif
AU - Mehaj, Mirsad
AU - Seetharaman, Natasha
AU - Yao, Helen F.
AU - Clancy, Donald J.
AU - Bilgili, Ecevit
N1 - Funding Information:
The authors thank Dr. Sayantan Chattoraj of GSK for his invaluable comments on the first draft of this manuscript. The first and last authors thank Nisso America Inc. for donating HPC.
Funding Information:
This study was funded by GlaxoSmithKline (GSK) through the Research & Development Service Agreement with NJIT entitled “Advanced Modeling of Pharmaceutical Wet Stirred Media Milling Process for the Production of Drug Nanosuspensions” [NJIT Grant Code G2718B0].
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/9
Y1 - 2022/9
N2 - Purpose: Nanosuspensions have been used for enhancing the bioavailability of poorly soluble drugs. This study explores the temperature evolution during their preparation in a wet stirred media mill using a coupled experimental–enthalpy balance approach. Methods: Milling was performed at three levels of stirrer speed, bead loading, and bead sizes. Temperatures were recorded over time, then simulated using an enthalpy balance model by fitting the fraction of power converted to heat ξ. Moreover, initial and final power, ξ, and temperature profiles at 5 different test runs were predicted by power-law (PL) and machine learning (ML) approaches. Results: Heat generation was higher at the higher stirrer speed and bead loading/size, which was explained by the higher power consumption. Despite its simplicity with a single fitting parameter ξ, the enthalpy balance model fitted the temperature evolution well with root mean squared error (RMSE) of 0.40–2.34°C. PL and ML approaches provided decent predictions of the temperature profiles in the test runs, with RMSE of 0.93–4.17 and 1.00–2.17°C, respectively. Conclusions: We established the impact of milling parameters on heat generation–power and demonstrated the simulation–prediction capability of an enthalpy balance model when coupled to the PL–ML approaches. Graphical abstract: [Figure not available: see fulltext.]
AB - Purpose: Nanosuspensions have been used for enhancing the bioavailability of poorly soluble drugs. This study explores the temperature evolution during their preparation in a wet stirred media mill using a coupled experimental–enthalpy balance approach. Methods: Milling was performed at three levels of stirrer speed, bead loading, and bead sizes. Temperatures were recorded over time, then simulated using an enthalpy balance model by fitting the fraction of power converted to heat ξ. Moreover, initial and final power, ξ, and temperature profiles at 5 different test runs were predicted by power-law (PL) and machine learning (ML) approaches. Results: Heat generation was higher at the higher stirrer speed and bead loading/size, which was explained by the higher power consumption. Despite its simplicity with a single fitting parameter ξ, the enthalpy balance model fitted the temperature evolution well with root mean squared error (RMSE) of 0.40–2.34°C. PL and ML approaches provided decent predictions of the temperature profiles in the test runs, with RMSE of 0.93–4.17 and 1.00–2.17°C, respectively. Conclusions: We established the impact of milling parameters on heat generation–power and demonstrated the simulation–prediction capability of an enthalpy balance model when coupled to the PL–ML approaches. Graphical abstract: [Figure not available: see fulltext.]
KW - enthalpy balance
KW - heat dissipation
KW - poorly water-soluble drugs
KW - process modeling
KW - wet stirred media milling
UR - http://www.scopus.com/inward/record.url?scp=85135278237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135278237&partnerID=8YFLogxK
U2 - 10.1007/s11095-022-03346-3
DO - 10.1007/s11095-022-03346-3
M3 - Article
C2 - 35915319
AN - SCOPUS:85135278237
SN - 0724-8741
VL - 39
SP - 2065
EP - 2082
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 9
ER -